KARYOPHARM THERAPEUTICS INC (KPTI) — insider trading
Health Care · NASDAQ
KARYOPHARM THERAPEUTICS INC (KPTI) has 18 reported SEC Form 4 insider transactions in our data, including 6 open-market sales among the most recent 18 (latest 2026-05-21).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-05-21 | Greene Barry E | Director | Grant / award / vesting | 15,508 | $0.00 | $0 | Form 4 |
| 2026-05-21 | BOHLIN GAREN G | Director | Grant / award / vesting | 15,508 | $0.00 | $0 | Form 4 |
| 2026-05-21 | Su Zhen | Director | Grant / award / vesting | 15,508 | $0.00 | $0 | Form 4 |
| 2026-05-21 | Schor Chen | Director | Grant / award / vesting | 15,508 | $0.00 | $0 | Form 4 |
| 2026-05-21 | PAKIANATHAN DEEPIKA | Director | Grant / award / vesting | 15,508 | $0.00 | $0 | Form 4 |
| 2026-05-21 | Oliger Christy J. | Director | Grant / award / vesting | 15,508 | $0.00 | $0 | Form 4 |
| 2026-05-14 | Mano Michael | Officer (EVP, CLO&Secretary) | Open-market sale | 266 | $9.50 | $2.5K | Form 4 |
| 2026-05-14 | Paulson Richard A. | Director, Officer (President and CEO) | Open-market sale | 2,203 | $9.50 | $20.9K | Form 4 |
| 2026-05-14 | Abate Kristin | Officer (Chief Accounting Officer) | Open-market sale | 53 | $9.50 | $504 | Form 4 |
| 2026-05-14 | Cheng Sohanya Roshan | Officer (EVP & Chief Commercial Officer) | Open-market sale | 324 | $9.50 | $3.1K | Form 4 |
| 2026-05-14 | Rangwala Reshma | Officer (EVP & Chief Medical Officer) | Open-market sale | 408 | $9.50 | $3.9K | Form 4 |
| 2026-05-14 | Poulton Stuart | Officer (EVP, Chief Development Officer) | Open-market sale | 403 | $9.50 | $3.8K | Form 4 |
| 2026-05-13 | Mano Michael | Officer (EVP, CLO&Secretary) | Grant / award / vesting | 700 | $0.00 | $0 | Form 4 |
| 2026-05-13 | Paulson Richard A. | Director, Officer (President and CEO) | Grant / award / vesting | 4,920 | $0.00 | $0 | Form 4 |
| 2026-05-13 | Abate Kristin | Officer (Chief Accounting Officer) | Grant / award / vesting | 121 | $0.00 | $0 | Form 4 |
| 2026-05-13 | Cheng Sohanya Roshan | Officer (EVP & Chief Commercial Officer) | Grant / award / vesting | 947 | $0.00 | $0 | Form 4 |
| 2026-05-13 | Rangwala Reshma | Officer (EVP & Chief Medical Officer) | Grant / award / vesting | 947 | $0.00 | $0 | Form 4 |
| 2026-05-13 | Poulton Stuart | Officer (EVP, Chief Development Officer) | Grant / award / vesting | 896 | $0.00 | $0 | Form 4 |
Ask the chat about KPTI's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: KARYOPHARM THERAPEUTICS INC (KPTI).
Last updated 2026-05-21 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.